Adam Mecca
Psychiatry · New Haven, CTNPI 1033485263
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,600 of the $6,015 with a category attached, or 76.5%. AbbVie accounts for 76.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $4,600 and has fallen 70.9% since, to $1,339 in 2025. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 12 payments — averaging $501.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Merck$1K
- Eisai Inc.$76
- Axsome Therapeutics, Inc.$46
Across 355 payments — averaging $14,291 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.6M
- Janssen Research & Development, LLC$1.5M
- Genentech, Inc.$582K
- Eisai Inc.$399K
What the payments were for
- Consulting fees$4,60076%
- Travel & lodging$93816%
- Food & beverage$4778%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $4,600 |
| Merck | 9 | $1,293 |
| Eisai Inc. | 1 | $76 |
| Axsome Therapeutics, Inc. | 1 | $46 |
How this compares
$6,015 in reported general payments places this provider in the 90th percentile of 644 psychiatry providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Donepezil Hcl | 129 | $1,235 |
| Escitalopram Oxalate | 91 | $971 |
| Mirtazapine | 14 | $712 |
| Memantine Hcl | 36 | $469 |
| Quetiapine Fumarate | 16 | $196 |
| Sertraline Hcl | 12 | $124 |
| Clonazepam | 12 | $85 |
| Buspirone Hcl | 11 | $7 |
| Lorazepam | 15 | $6 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New Haven
- Vladimir CoricNew Haven$133.7M
- Robert BermanNew Haven$126K
- Gerard SanacoraNew Haven$94K
- Christopher VandyckNew Haven$70K
- Paula ZimbreanNew Haven$61K
- Brandon KitayNew Haven$59K
- Sarah FinebergNew Haven$34K
- Samuel WilkinsonNew Haven$30K
- Christopher PittengerNew Haven$19K
- Dan OrenNew Haven$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.